A rapid RT-PCR based method for the detection of BCR-ABL translocation.

Sidorova, Zh Yu; Saltykova, L B; Lyschov, AntonA; Zaritskey, AYu; Abdulkadyrov, Kudrat; Blinov, M N

doi:10.1136/mp.50.5.266

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lentiviral pHIV7-GFP vector containing the shRNA specific for the b3a2 (e14a2) translocation breakpoint of BCR/ABL was provided by J. Rossi (Beckman Research Institute, City of Hope, Duarte, California, USA). Prior to transduction, the presence of the b3a2 BCR-ABL1 translocation was assessed by RT-PCR, as previously described (57). pBAR and pfuBAR.…”

Section: Figurementioning

confidence: 99%

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

et al. 2013

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

et al. 2013

View full text Add to dashboard Cite

“…Guo et al have shown that the BCR-ABL gene is highly expressed in myelogenous leukemia cells [23]. In addition, Yu et al showed that real-time qRT-PCR was able to detect the mRNA produced by the BCR-ABL gene [24].…”

Section: Resultsmentioning

confidence: 99%

Dielectrophoretic high-purity isolation of primary T-cells in samples contaminated with leukemia cells, for biomanufacturing of therapeutic CAR T-cells

Ringwelski¹,

Jayasooriya²,

Nawarathna³

2020

J. Phys. D: Appl. Phys.

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy is a Food and Drug Administration (FDA)-approved treatment for specific cancers. CAR T-cells are manufactured ex vivo using T-cells derived from patients. Recent clinical trials reported a very high level of efficacy as well as complete remission rates (70%–93%) for acute lymphoblastic leukemia (ALL) patients. However, there have also been reports of significant adverse effects resulting from the contamination of T-cells derived from patients with existing cancer cells during manufacturing. The accidental transfection of cancer cells with CAR genes provides the cancer cells with immunity from CAR T-cells. As a result, genetically modified cancer cells that express the CAR molecules grow into secondary tumors. This significantly undermines the great benefits offered by CAR T-cell therapy. The removal of cancer cells before gene transfer using cell purification methods can address this issue. However, traditional cell purification methods such as fluorescence-activated cell separation and magnetic-activated cell separation have proven to be unsuitable for high-purity T-cell purification. To address this issue, we investigated the utility, in microfluidic channels, of dielectrophoretic cell purification, which is a label-free high-throughput cell purification method. When we conducted the experiments with primary T-cell (CD8+) samples contaminated with cultured acute lymphoblastic leukemia and chronic myelogenous leukemia cells, we found that dielectrophoresis could be used to purify cell samples and achieve 100% purity with high cell viability (greater than 90%).

show abstract

“…The first assays to screen cancer patients for somatic alterations targetable by drugs were based on detection of single gene alterations [8]. For example, early studies investigating the genomic landscapes of breast cancers identified HER2 copy number amplifications in ~30% of patients, noting that overexpression of HER2 was associated with poor prognosis [9].…”

mentioning

confidence: 99%

Sequencing Strategies to Guide Decision Making in Cancer Treatment

Topham¹,

Marra²

2016

PLoS Med

View full text Add to dashboard Cite

show abstract

A rapid RT-PCR based method for the detection of BCR-ABL translocation.

Abstract: The suggested one step PCR strategy is a simple and reliable way to reveal BCR-ABL chimaeras.

Cited by 6 publications

References 16 publications

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Dielectrophoretic high-purity isolation of primary T-cells in samples contaminated with leukemia cells, for biomanufacturing of therapeutic CAR T-cells

Sequencing Strategies to Guide Decision Making in Cancer Treatment

Contact Info

Product

Resources

About